Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. (2022). Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases. Research in Oncology, 18(2), 45-51. doi: 10.21608/resoncol.2022.135734.1166
Elia F. Hakim; Amina M. Mostafa; Mohamed A. H. Mohamed; Mahmoud F. A. Sherif; Maha S. El Naggar. "Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases". Research in Oncology, 18, 2, 2022, 45-51. doi: 10.21608/resoncol.2022.135734.1166
Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. (2022). 'Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases', Research in Oncology, 18(2), pp. 45-51. doi: 10.21608/resoncol.2022.135734.1166
Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases. Research in Oncology, 2022; 18(2): 45-51. doi: 10.21608/resoncol.2022.135734.1166
Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases
1Department of Clinical Oncology, Sohag Cancer Center, Sohag, Egypt
2Department of Clinical Oncology, Assuit University, Assuit, Egypt
3Department of Pathology, Assuit University, Assuit, Egypt
Abstract
Background: Tumor-infiltrating lymphocytes (TILs) were found to be associated with a better clinical outcome in specific subtypes of breast cancer. Aim: To study the association between TILs and the prognosis of Egyptian patients with HER2-negative breast cancer metastatic to the viscera. Methods: This prospective study included 100 patients with HER2-negative metastatic breast cancer. Intratumoral TILs, stromal TILs, and CD4 and CD8 were examined in the pathological specimens and their relationship with survival and response to treatment was studied. Results: At a median follow-up period of 43 months, the median overall survival was 44.7 months (95%CI: 39.2-50.2) and the 5-year overall survival rate was 28%. A high level of CD8+ve TILs was associated with significantly longer overall survival (p < 0.001) and progression-free survival (p=0.043). There was no significant correlation between intratumoral TILs, stromal TILs, or CD4+ve and overall survival. Conclusions: A higher level of CD8+ve TILs is associated with better overall as well as progression-free survival in HER2-negative breast cancer with visceral metastases.
View on SCiNiTO
Top